Listed

NETWORK-1 Technologies, Inc.: Form 10-Q for the period ended Jun 30, 2026

Filed with the SEC on Aug 6, 2026 and accepted by EDGAR at Aug 6, 2026, 16:31 ET.

Share

Management's discussion and analysis

As filed, 19,012 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q.

OVERVIEW

Our principal business is the development, licensing and protection of our intellectual property assets. We presently own one hundred twenty- one (121) U.S. patents, fifty-four (54) of which have expired, and fifteen (15) foreign patents (unexpired) relating to: (i) our M2M/IoT Patent Portfolio relating to, among other things, enabling technology for authenticating and using eSIM (embedded Subscriber Identification Module) technology in IoT, Machine-to-Machine and other mobile devices, including smartphones, tablets and computers, as well as automobiles; (ii) our HFT Patent Portfolio covering certain advanced technologies relating to high frequency trading, which inventions specifically address technological problems associated with speed and latency and provide critical latency gains in trading systems; (iii) our Cox Patent Portfolio relating to enabling technology for identifying media content on the internet and taking further action to be performed after such identification; (iv) our Smart Home Patent Portfolio relating to, among other things, the enabling technology to support the interoperability of smart home IoT devices.

At June 30, 2026, our principal sources of liquidity consisted of cash and cash equivalents and marketable securities of $33,752,000 and working capital of $33,179,000. Based on our cash position, we review opportunities to acquire additional intellectual property as well as evaluate other strategic opportunities.

Our future revenue is dependent on our ability to monetize our M2M/IOT Patent Portfolio, HFT Patent Portfolio, Cox Patent Portfolio and Smart Home Patent Portfolio. If we are unable to successfully monetize such patent portfolios or achieve a successful outcome of our investment in ILiAD, our business, financial condition and results of operations will be negatively impacted.

We have four pending litigations involving certain patents within our M2M/IoT Patent Portfolio, HFT Patent Portfolio and Cox Patent Portfolio (see “Legal Proceedings” at pages 19 – 20 hereof). We may not achieve successful outcomes of such litigation, or future litigation involving our patent assets.

Our current strategy includes continuing our licensing efforts with respect to our intellectual property assets and the monetization of our patent portfolios. In addition, we continue to seek to acquire additional intellectual property assets to develop, commercialize, license or otherwise monetize. Our strategy includes working with inventors and patent owners to assist in the development and monetization of their patented technologies. We may also enter into strategic relationships with third parties to develop, commercialize, license or otherwise monetize their intellectual property. Our patent acquisition and development strategy is to focus on acquiring high quality patents which management believes have the potential to generate significant licensing opportunities as we have achieved with respect to our Remote Power Patent and Mirror Worlds Patent Portfolio.

To date we have invested $7,000,000 in ILiAD, a clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis with a focus on validating its proprietary intranasal vaccine, BPZE1, for the prevention of pertussis (see Note K to our unaudited condensed consolidated financial statements included herein). On February 5, 2026, ILiAD completed a $115,000,000 preferred stock financing. As part of the financing, ILiAD converted from a limited liability company to a corporation. The financing was led by RA Capital Management with participation from new investors Janus Henderson Investors and BNP Paribas Asset Management Alts, as well as existing investors including a multi-national pharmaceutical company and AI Life Sciences. As a result of the financing, the Company’s percentage ownership of ILiAD was reduced to approximately 2.5% on a fully diluted basis. As a result of the financing, we no longer account for our investment in ILiAD using the equity method of accounting and now we use the cost method of accounting (see Note B[3] and Note K of our unaudited condensed consolidated financial statements included herein).

The significant components of expenses, when revenue is recorded, that may impact our net income (loss) relate to contingent legal fees and expenses related to our patent litigation contingent payments related to patent acquisitions (see Note H[1] and Note H[2] hereof) to our unaudited condensed consolidated financial statements included herein) and incentive compensation payable to our Chairman and Chief Executive Officer pursuant to the surviving provisions of his prior employment agreement (see Note I[1] to our unaudited condensed consolidated financial statements included herein). All such components of expenses are based on a percentage of the revenue received by us as a result of litigation or otherwise.

Our quarterly and annual operating and financial results may fluctuate significantly from period-to-period as a result of a variety of factors that are outside our control, including the timing and our ability to achieve successful outcomes of our patent litigation, our ability and timing of consummating future license agreements for our intellectual property, and whether we will achieve a return on our investment in ILiAD and the timing of any such return.

Our future operating results may also be materially impacted by our ability to acquire high quality patents which management believes have the potential to generate significant licensing opportunities. In the future, we may not be able to identify or consummate such patent acquisitions or, if consummated, achieve significant licensing revenue with respect to such acquisitions.

In 2026 and future years we could be classified as a Personal Holding Company. If this is the case, we would be subject to a 20% tax on the amount of any undistributed personal holding company income (as defined) for such year that we do not distribute to our shareholders (see Note B[4] to our unaudited condensed consolidated financial statements included herein).

Our current dividend policy consists of semi-annual cash dividends of $0.05 per share ($0.10 per share annually) which have been paid in March and September of each year. To date, we have paid semi-annual cash dividends in accordance with our dividend policy. At this time, we anticipate continuing to pay dividends consistent with our policy. However, our dividend policy undergoes a periodic review by our Board of Directors and is subject to change at any time depending upon our financial requirements, earnings and other factors existing at the time (see Note N to our unaudited condensed consolidated financial statements included herein).

RESULTS OF OPERATIONS

Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025

Revenue. We had no revenue for the three months ended June 30, 2026 and June 30, 2025. We currently have four pending patent infringement litigations involving certain patents within our HFT Patent Portfolio, M2M/IoT Patent Portfolio and Cox Patent Portfolio (see Note J to our unaudited condensed consolidated financial statements included herein).

Operating Expenses. Operating expenses for the three months ended June 30, 2026 were $1,013,000 as compared to $720,000 for the three months ended June 30, 2025. The increase in operating expenses of $293,000 was primarily due to increased litigation related costs of $337,000 offset by decreased restricted stock compensation expense of $38,000.

Interest and Dividend Income. Interest and dividend income for the three months ended June 30, 2026 was $350,000 as compared to $445,000 for the three months ended June 30, 2025. The decrease of $95,000 was a result of decreased funds available for investment in marketable securities in 2026, as well as such investments being made in lower yielding fixed income investments as a result of prevailing interest rate market conditions.

Income Taxes. For the three months ended June 30, 2026, we had no current income tax expense as compared to a $31,000 current tax benefit related to a federal income tax refund for the same period in 2025. For the three months ended June 30, 2026, we had no deferred income taxes as compared to a deferred tax benefit of $38,000 for the three months ended June 30, 2025. The decrease in our deferred income tax benefit was the result of no longer recognizing our share of the net losses of our equity method investee (ILiAD) in 2026.

Share of Net Losses of Equity Method Investee. As a result of the conversion to the fair value method of accounting for our equity investment, we recognized no net losses during the three month period ended June 30, 2026 as compared to $279,000 of net losses under the equity method of accounting during the three month period ended June 30, 2025.

Net Loss. As a result of the foregoing, we realized a net loss of $655,000 or $0.03 per share basic and diluted for the three months ended June 30, 2026, compared with a net loss of $463,000 or $0.02 per share basic and diluted for the three months ended June 30, 2025. The increase in our net loss of $192,000 for the three months ended June 30, 2026, as compared to the same period in 2025, was the result of increased operating expenses of $293,000, decreased other income of $109,000 and decreased income tax benefits of $69,000, offset somewhat by the decrease in our share of net loss of equity method investee of $279,000.

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025

Revenue. We had no revenue for the six months ended June 30, 2026 and $150,000 in revenue for the six months ended June 30, 2025. We currently have four pending patent infringement litigations involving certain patents within our HFT Patent Portfolio, M2M/IoT Patent Portfolio and Cox Patent Portfolio (see Note J to our unaudited condensed consolidated financial statements included herein).

Operating Expenses. Operating expenses for the six months ended June 30, 2026 were $2,428,000 as compared to $1,515,000 for the six months ended June 30, 2025. The increase in operating expenses of $913,000 was primarily as a result of increased professional fees and related costs of $971,000, as a result of increased litigation related costs of $962,000, offset by reduced costs of revenue of $42,000 due to no revenue in the period ended June 30, 2026.

Interest and Dividend Income. Interest and dividend income for the six months ended June 30, 2026 was $734,000 as compared to $929,000 for the six months ended June 30, 2025. The decrease of $195,000 was a result of decreased funds available for investment in marketable securities in 2026, as well as such investments being made in lower yielding fixed income investments as a result of prevailing interest rate market conditions.

Gain on Equity Investment. For the six months ended June 30, 2026, as a result of ILiAD’s private financing completed in February 2026 and the resulting change in our accounting for the investment from the equity method to the cost method, we recorded a gain on our equity investment in ILiAD of $1,052,000 (see Note K and Note B[3] to our unaudited condensed consolidated financial statements included herein).

Realized and Unrealized Gain (Loss) on Marketable Securities. For the six months ended June 30, 2026, we recorded realized and unrealized losses on marketable securities of $279,000, as compared to realized and unrealized gains of $171,000 for the six months ended June 30, 2025. The decrease of $450,000 was primarily due to unrealized losses of $84,000 as of June 30, 2026 on our marketable securities, compared to unrealized gains of $257,000 at December 31, 2025. The decrease reflects a decline in the market value of U.S. government securities, fixed income mutual funds and corporate bonds and notes held by us. During the period ended June 30, 2026, short-term Treasury yields increased, which resulted in lower market prices for our fixed-income securities.

Income Taxes. For the six months ended June 30, 2026, we had no current income tax expense as compared to a $31,000 current tax benefit related to a federal income tax refund for the same period in 2025. We had a deferred tax expense of $245,000 for the six months ended June 30, 2026 compared to a deferred tax benefit of $149,000 for the six months ended June 30, 2025. The increase of $394,000 in our deferred income taxes was primarily the result of deferred income tax expense of $245,000 recorded in 2026 in connection with the gain on our equity investment (ILiAD) and no deferred income tax benefit as a result of no longer recognizing our share of the losses of our equity method investee, as compared to $149,000 of deferred tax benefit as a result of our recognized net losses of our equity method investee (ILiAD) for the six months ended June 30, 2025.

Share of Net Losses of Equity Method Investee. As a result of the conversion to the fair value method of accounting for our equity investment, we recognized no net losses during the six months period ended June 30, 2026 as compared to $741,000 of net losses during the six month period ended June 30, 2025 as a result of application of the equity method of accounting.

Net Loss. As a result of the foregoing, we realized a net loss of $1,166,000 or $0.05 per share basic and diluted for the six months ended June 30, 2026, compared with a net loss of $826,000 or $0.04 per share basic and diluted for the six months ended June 30, 2025. The increase in net loss of $340,000 for the six months ended June 30, 2026, as compared to 2025, was primarily the result of decreased revenue of $150,000, increased operating expenses of $913,000, decreased interest and dividend income of $195,000, increased realized and unrealized loss on marketable securities of $450,000 and increased income taxes of $425,000, offset by increased gain on equity investment of $1,052,000 and decreased recognized losses of our equity method investee of $741,000.

LIQUIDITY AND CAPITAL RESOURCES

We have financed our operations primarily from revenue from licensing our patents. At June 30, 2026, our principal sources of liquidity consisted of cash and cash equivalents and marketable securities of $33,752,000 and working capital of $33,179,000. Based on our current working capital position, we believe that we will have sufficient liquidity to fund our operations for the next twelve months and the foreseeable future. Our pending patent infringement litigations or realization of our investment in ILiAD may result in a material increase in our liquidity and capital resources.

Working capital decreased by $3,157,000 at June 30, 2026 to $33,179,000 as compared to working capital of $36,336,000 at December 31, 2025. The decrease during the six month period ended June 30, 2026 was primarily attributed to the net cash used in operating activities of $1,242,000, dividend payments of $1,140,000, the acquisition of patents of $250,000 and repurchases of common stock of $136,000.

Net cash used in operating activities increased by $740,000 to $1,242,000 for the six months ended June 30, 2026 from $502,000 for the six months ended June 30, 2025. The increase in net cash used in operating activities was primarily attributable to an increase in our net loss of $340,000, a non-cash gain on our equity investment of $1,052,000 in 2026, the reduction in the loss on our equity method investment recognized in 2025 of $741,000. These uses of cash were offset by an increase in our unrealized loss on marketable securities of $510,000, increased accounts payable of $402,000 and an increase in the deferred tax expense of $394,000.

Net cash used in investing activities during the six months ended June 30, 2026 increased by $3,590,000 to $1,440,000 used in investing activities as compared to $2,150,000 provided by investing activities for the six months ended June 30, 2025. The increase in the net cash used in investing activities is primarily as a result of reduced sales of marketable securities of $2,444,000 and increased purchases of marketable securities of $1,310,000, offset by reduced acquisitions of patents of $164,000.

Net cash used in financing activities for the six months ended June 30, 2026 and 2025 was $1,285,000 and $1,369,000, respectively. The decrease in net cash used in financing activities of $84,000 primarily resulted from the decrease in stock repurchases of $71,000.

We maintain our cash in money market funds, government securities, certificates of deposit, corporate bonds and notes, and short-term fixed income securities. Accordingly, we do not believe that our investments have significant exposure to interest rate risk.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements.

CONTRACTUAL OBLIGATIONS

We do not have any long-term debt, capital lease obligations, purchase obligations or other long-term liabilities.

CRITICAL ACCOUNTING ESTIMATES

Our unaudited condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our financial statements included in this Quarterly Report on Form 10-Q requires management to make estimates that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking account of our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.

We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from the period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statements that require estimation but are not deemed critical, as defined above.

For a detailed discussion of our significant accounting policies and related judgements, see Note B to our unaudited condensed consolidated financial statements included herein.

Controls and procedures

As filed, 1,220 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(a) Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this review, these officers concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in applicable rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls

There was no change in our internal control over financial reporting that occurred during the fiscal quarter ended June 30, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 471 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations and the trading price of our common stock. Investors should carefully consider the risks described in this Quarterly Report on Form 10-Q for the three months ended June 30, 2026, and our Annual Report on Form 10-K for the year ended December 31, 2025 (pages 9-18), filed with the SEC on March 13, 2026.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2026-04-01 to 2026-06-30−$1.0mus-gaap:OperatingIncomeLoss
Operating income6 months2026-01-01 to 2026-06-30−$2.4mus-gaap:OperatingIncomeLoss
Income tax6 months2026-01-01 to 2026-06-30$245.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-04-01 to 2026-06-30−$655.0kus-gaap:NetIncomeLoss
Net income6 months2026-01-01 to 2026-06-30−$1.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-04-01 to 2026-06-30−$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2026-01-01 to 2026-06-30−$0.05us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-04-01 to 2026-06-30−$0.03us-gaap:EarningsPerShareBasic
Basic EPS6 months2026-01-01 to 2026-06-30−$0.05us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-04-01 to 2026-06-3022,836,456 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2026-01-01 to 2026-06-3022,824,937 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$1.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Dividends paid6 months2026-01-01 to 2026-06-30$1.1mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases6 months2026-01-01 to 2026-06-30$136.0kus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-06-30$9.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-06-30$33.9mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$38.5mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$722.0kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-06-30$967.0kus-gaap:Liabilities
Shareholders' equityAt period end2026-06-30$37.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001072613-26-000626. Last ingested by Listed: Nov 10, 2026, 02:17 ET. Listed shows no prices and gives no investment advice.